Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2010 1
2011 3
2012 5
2014 2
2015 3
2016 1
2017 2
2018 3
2019 2
2021 3
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
Pellegrino B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, Moles-Fernández A, Viaplana C, Villacampa G, Guzmán M, Rodríguez O, Grueso J, Jiménez J, Arenas EJ, Degasperi A, Dias JML, Forment JV, O'Connor MJ, Déas O, Cairo S, Zhou Y, Musolino A, Caldas C, Nik-Zainal S, Clarke RB, Nuciforo P, Díez O, Serres-Créixams X, Peg V, Espinosa-Bravo M, Macarulla T, Oaknin A, Mateo J, Arribas J, Dienstmann R, Bellet M, Oliveira M, Saura C, Gutiérrez-Enríquez S, Balmaña J, Serra V. Pellegrino B, et al. Among authors: forment jv. Cancer Res. 2022 Apr 15;82(8):1646-1657. doi: 10.1158/0008-5472.CAN-21-2409. Cancer Res. 2022. PMID: 35425960 Free PMC article.
Mechanisms of PARP Inhibitor Resistance.
O'Connor MJ, Forment JV. O'Connor MJ, et al. Among authors: forment jv. Cancer Treat Res. 2023;186:25-42. doi: 10.1007/978-3-031-30065-3_3. Cancer Treat Res. 2023. PMID: 37978129
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.
Zelceski A, Francica P, Lingg L, Mutlu M, Stok C, Liptay M, Alexander J, Baxter JS, Brough R, Gulati A, Haider S, Raghunandan M, Song F, Sridhar S, Forment JV, O'Connor MJ, Davies BR, van Vugt MATM, Krastev DB, Pettitt SJ, Tutt ANJ, Rottenberg S, Lord CJ. Zelceski A, et al. Among authors: forment jv. Cell Rep. 2023 May 30;42(5):112484. doi: 10.1016/j.celrep.2023.112484. Epub 2023 May 9. Cell Rep. 2023. PMID: 37163373 Free article.
Targeting the replication stress response in cancer.
Forment JV, O'Connor MJ. Forment JV, et al. Pharmacol Ther. 2018 Aug;188:155-167. doi: 10.1016/j.pharmthera.2018.03.005. Epub 2018 Mar 24. Pharmacol Ther. 2018. PMID: 29580942 Review.
Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing.
Wimberger S, Akrap N, Firth M, Brengdahl J, Engberg S, Schwinn MK, Slater MR, Lundin A, Hsieh PP, Li S, Cerboni S, Sumner J, Bestas B, Schiffthaler B, Magnusson B, Di Castro S, Iyer P, Bohlooly-Y M, Machleidt T, Rees S, Engkvist O, Norris T, Cadogan EB, Forment JV, Šviković S, Akcakaya P, Taheri-Ghahfarokhi A, Maresca M. Wimberger S, et al. Among authors: forment jv. Nat Commun. 2023 Aug 14;14(1):4761. doi: 10.1038/s41467-023-40344-4. Nat Commun. 2023. PMID: 37580318 Free PMC article.
C16orf72/HAPSTR1/TAPR1 functions with BRCA1/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruption.
Sharma AB, Ramlee MK, Kosmin J, Higgs MR, Wolstenholme A, Ronson GE, Jones D, Ebner D, Shamkhi N, Sims D, Wijnhoven PWG, Forment JV, Gibbs-Seymour I, Lakin ND. Sharma AB, et al. Among authors: forment jv. Nat Commun. 2023 Aug 17;14(1):5003. doi: 10.1038/s41467-023-40779-9. Nat Commun. 2023. PMID: 37591890 Free PMC article.
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, Jones GN, Lai Z, Armenia J, Michopoulos F, Llop-Guevara A, Brough R, Gulati A, Pettitt SJ, Bulusu KC, Nikkilä J, Wilson Z, Hughes A, Wijnhoven PWG, Ahmed A, Bruna A, Gris-Oliver A, Guzman M, Rodríguez O, Grueso J, Arribas J, Cortés J, Saura C, Lau A, Critchlow S, Dougherty B, Caldas C, Mills GB, Barrett JC, Forment JV, Cadogan E, Lord CJ, Cruz C, Balmaña J, O'Connor MJ. Serra V, et al. Among authors: forment jv. Clin Cancer Res. 2022 Oct 14;28(20):4536-4550. doi: 10.1158/1078-0432.CCR-22-0568. Clin Cancer Res. 2022. PMID: 35921524 Free PMC article.
Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition.
Jamal K, Galbiati A, Armenia J, Illuzzi G, Hall J, Bentouati S, Barrell D, Ahdesmäki M; Functional Genomics Centre Group; O'Connor MJ, Leo E, Forment JV. Jamal K, et al. Among authors: forment jv. Cancer Res Commun. 2022 Oct 21;2(10):1244-1254. doi: 10.1158/2767-9764.CRC-22-0119. eCollection 2022 Oct. Cancer Res Commun. 2022. PMID: 36969741 Free PMC article.
35 results